Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

Royalty Pharma plc (RPRX) will report its Q1 2022 financial results on May 5, 2022, before U.S. markets open. A conference call will be held at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, founded in 1996, is a leader in buying biopharmaceutical royalties, with a portfolio covering over 35 commercial products. It collaborates with various innovators to fund clinical trials and product launches, securing future royalties. More details can be found on their official website.

Positive

• Royalty Pharma has a diverse portfolio of royalties on more than 35 commercial products.
• The company collaborates with a range of innovators, enhancing its market position.

Negative

• None.

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 1288402.

A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnsons’ Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When will Royalty Pharma report its first quarter 2022 financial results?

Royalty Pharma will report its Q1 2022 financial results on May 5, 2022.

What time is the Royalty Pharma conference call for Q1 2022 results?

The conference call is scheduled for 8:00 a.m. Eastern Time on May 5, 2022.

How can I access the Royalty Pharma Q1 2022 financial results conference call?

The conference call can be accessed by dialing (833) 519-1253 for U.S. callers or +1 (914) 800-3826 for international callers, using the passcode 1288402.

Where can I find more information about Royalty Pharma's financial results?

Additional information can be found on the Investors page of Royalty Pharma's website.